Compare Check Point Software Technologies Ltd (CHKP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Check Point Software Technologies Ltd vs Mesoblast Limited — how do they compare? Check Point Software Technologies Ltd trades at $129.28 (market cap $13.20B), while Mesoblast Limited trades at $16.74 (market cap $2.20B). The key difference: Check Point Software Technologies Ltd is far larger — about 6× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| CHKP | MESO | |
|---|---|---|
Market Cap | $13.20B | $2.20B |
Sector | Technology | Technology |
52-Week High | $206.91 | $20.96 |
52-Week Low | $112.47 | $12.88 |
Enterprise Value | $12.90B | $2.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHKP trades at $129.29, down 1.41% today, with a bearish technical signal as it hovers near support at $128. The stock shows strong fundamentals with a P/E of 13.24, net income margin of 37.93%, and consistent earnings beats in recent quarters. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a consensus price target of $146.92, but near-term risks include competitive pressures and margin declines. Upside depends on AI-driven revenue acceleration in 2027, while downside is capped by solid cash flow and profitability.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
